Discover and read the best of Twitter Threads about #oncology

Most recents (14)

"Ever get the feeling you've been cheated?" (John Lydon)

The publication of this letter & the nature of its correction raises questions about the reliability of the academic record.

@llantwit @FFLMUK @RCPath @AAPTTweets @mike4path @Richard56 @JJPJ #autopsy

THREAD

1/14
When the letter by Won Sriwijitalai & Viroj Wiwanitkit was published in #JFLM, fact-checking journalists @SureAndShare in Thailand shared their concerns about it on @Twitter & @Facebook.

2/14
@SureAndShare were concerned that they were unable to verify who the 1st author was (or where they worked), or the death of a #forensic #medical professional from #COVID19. They cautioned against sharing the story.

3/14
Read 15 tweets
Here are some additional slides from my presentation I gave to the @MDAndersonNews #Oncology healthcare providers. While I covered a lot, here is further information on #therapeutics for #COVID19

Not enough time to discuss everything so I highlighted a few.
Read 18 tweets
Thanks to all my colleagues for voting. This is an interesting question in breast oncology, and practice varies quite a bit (As you can see from the poll)
#medtwitter #breastcancer #OncoAlert #chemo #courtingcontroversy
#oncology
#tweetorial

Thread
1/6
There is interest in getting rid of anthracyclines from adjuvant chemotherapy of breast cancer, due to long-term concerns of heart failure and secondary leukemia. The ABC meta-analysis seemed to concur that taxane+anthracycline (TaxAC) beats 6TC by a small margin
2/6
An unplanned subgroup analysis revealed interaction with number of nodes in HR+ patients, with no benefit in HR+ N0 disease.
3/6
Read 6 tweets
Thread: I am getting tons of msgs from fellows since a few recent talks at @hopkinskimmel, @SocTransOnc Fellows Forum, etc, + Twitter. I am happy to hear from all of you, esp the many people interested in #regulatory science. But many similar Qs, so here goes w/ resources!
@hopkinskimmel @SocTransOnc The #FDA_ASCOFellowsDay is a 1d workshop for #hematology & #oncology fellows in last yr (+ lim # of next to last yr) of training. It happens 2x/yr (fall & spring) on FDA campus in MD & 1x/yr at @ASCO Annual Mtg (1/2 day on Fri am). Applications for #ASCO20 one will open soon. 2/X
@hopkinskimmel @SocTransOnc @ASCO Our next one at the FDA campus is coming up on 3/10/20 (already full). This is a screenshot w/ high-level overview of it, and here's the link where you'll find application instructions for the next one once it opens in a few wks: asco.org/training-educa… 3/X
Read 9 tweets
1/ Preventive Cardio-Oncology Tutorial #PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology

“The time has come for cardiovascular disease (CVD) prevention to play a more prominent role in cardio-oncology.”

tinyurl.com/PrevCardioOncT…
2/ “A myriad of novel cardiotoxic chemotherapeutic & immunotherapeutic drugs are continuously being developed in #Oncology, with diverse cardiovascular (CV) effects.”

tinyurl.com/PrevCardioOncT…

#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
3/ Chest radiation “can result in accelerated atherosclerosis, pericardial disease, valve disease, conduction abnormalities, & cardiomyopathies.”

tinyurl.com/PrevCardioOncT…

#PrevCardioOnc @PrevCardioOnc #CardioOnc #CardioOncology
Read 12 tweets
Here goes it! 🎙

Okay for all those non-oncology experts walking into this situation, let’s take a few steps back 🦶 and give a background on ibrutinib 👩‍🏫📜
Ibrutinib (Ibruvica®️) is a first in class ORAL 💊 Bruton tyrosine kinase (BTK) inhibitor,

Used for the treatment of a variety of B-cell lymphomas and Waldenstrom macroglobulinemia 🧬
Ibrutinub was a paradigm shift in the management of patients with CLL as initial or relapsed refractory cases

✅improved progression-free survival, ✅overall response rates, and ✅ overall survival

This was compared w/ ofatumumab (AKA rituximabs cousin) & ⚠️ chlorambucil ⚠️
Read 17 tweets
1/
Hi hi hi. We see lots of red flags on a daily basis when we review labs.

One thing we see commonly is #lymphopenia. Should we care? When can we dismiss it and when should we work it up?

Let’s find out.

#MedEd #MedTwitter #IDTwitter #Tweetorial #oncology
2/
- Lymphopenia assc w/ ⬆️risk of sepsis
- More common in elderly and w/ co-morbidities
- lymphs account for 20-40% of WBC, may go unnoticed when WBC checked w/o diff
- Primary- recurrent infxns in kids, CVID in adults
- Secondary-⬇️production; ⬆️destruction; hiding in tissue
3/
What is the most common cause of lymphopenia in hospitalized patients?
Read 14 tweets
1/
ACUTE SKIN GRAFT-VERSUS-HOST DISEASE:
A #tweetorial/#medthread on this complication of stem cell transplantation!

#MedEd #FOAMEd #dermtwitter #onctwitter #medtwitter #dermatology #dermatologia pc:@dermnetnz

1st, a poll:

How do you differentiate acute & chronic skin #GVHD?
2/
Acute vs. chronic GVHD is usually differentiated by when it occurs: before or after 100 days since allogeneic stem cell transplant. BUT in the skin, MORPHOLOGY is key!

As with almost everything else in derm, start with the exam. That will tell you what you're dealing with!
3/
Acute GVHD is usually morbilliform, which means "measles-like." Morphologically, we describe this eruption as "3-4 mm pink papules that coalesce into plaques." Whenever we see this in a SCT pt, the ddx includes the following:
- acute GVHD
- morbilliform drug
- viral exanthem
Read 14 tweets
Syphilis! RMSF! Hand-foot mouth!

Slow down there, Tiger! Let's dive deeper into:

ACRAL RASHES - a #tweetorial/#medthread
(aka rashes on the "palms and soles" - kind of 😉).

#MedEd #FOAMEd #medtwitter #dermtwitter #dermatology #dermatologia pc:@dermnetnz
1/
No where else on the body does a rash evoke more of a knee-jerk differential. That's not wrong per se, as we all learn this in med school, but it's more complicated then starting doxycycline and checking an RPR!

Let's start with a definition - what does "acral" actually mean?
2/
Technically, "acral" just means our distal body parts. So while we often think of palms and soles, it's actually inclusive of the whole hand, the whole foot, ears, and some include even the nose!

I actually didn't learn this until #derm residency, which was shocking to me.
3/
Read 20 tweets
Hey #tipsfornewdocs #medtwitter folks! I wanted to review side effects of immune checkpoint inhibitors (ICIs) for a non-#oncology audience. Immune-related adverse events (irAEs) present across all medicine specialties so we are all in this together. 1/x
The most common ICIs are against PD-1 (e.g. nivolumab, pembrolizumab) and PD-L1 (e.g. atezolizumab, durvalumab). I use a blanket term “PD-1” throughout. Anti-CTLA-4 (ipilimumab) is a distant second; often in combo or directly after PD-1 in #melanoma #lung #kidney cancers. 2/x
They have led to pharma riches and Nobel Prizes and lots of TV commercials because they work really well for some patients. People with advanced #melanoma, #lcsm etc who used to live ~1 year now can hope to live for several years or more. 3/x
Read 17 tweets
Hello new followers!👋 In honor of your joining me on Twitter, I thought I'd put together a new #dermatology #tweetorial/#medthread. This time, on a topic near and dear to my own clinical practice:

MYCOSIS FUNGOIDES!

#MedEd #FOAMEd #Dermtwitter #Medtwitter pc: @dermnetnz
1/
Let's start w/ caveats:
1-#MycosisFungoides (MF) isn't the same as Cutaneous T-cell Lymphoma. MF is a subtype of #CTCL; there are many other types of CTCL that aren't MF.
2-I co-direct the Skin Lymphoma Program @MGHCancerCenter, so some of this is institutional preference.
2/
There are roughly 80,000 new cases of #lymphoma a year in the US, and only 3% are primary cutaneous. Within that ~2500 cases, MF makes up almost half (~44%)! The overall classification schema for these diseases was recently updated by the WHO:
bloodjournal.org/content/133/16…
3/
Read 15 tweets
In honor of #skin #cancer awareness month, here's a #tweetorial on #SKINCANCER!

There is SO much we could talk about, so I'm going to keep it basic. #Dermtwitter, please add more!

#MedEd #FOAMed #dermatology #medtwitter @aadmember #dermatologia pc: @dermnetnz & @aadskin
1/
There are many types of skin cancer, but we'll focus on the big 3 in this #thread. We'll discuss basal cell carcinoma (BCC), Squamous cell carcinoma (SCC) & melanoma. The first two are types of "non-melanoma skin cancer (NMSC)," or more aptly named "keratinocytic carcinomas."
2/
BCCs are the most common cancer diagnosed. Classically described as "pink pearly papules," they often have "arborizing" (tree-like) telangiectasias. But, they don't always have to look classic. The 1st pic is the classic, but the others are also BCCs (superficial & pigmented)!
3/
Read 19 tweets
Last year, I made myself a haku lei (Hawaiian flower crown) for our white coat ceremony, and some classmates were interested, so I had the idea to have a workshop to teach them, and then I thought "how great would it be if we made them for patients??"
So I started looking into how to make this happen, and I found @MariaBaggstrom, who, among MANY other things, is the Oncology Interest Group faculty advisor. Talk about an amazing mentor and sponsor! She helped to connect me to the relevant parties and advised me throughout
my planning, and we were able to put on @WUSTLmed's very first #HappyHakuLei making workshop! I taught about 50 people how to make a haku lei, and then delivered the finished product to #gynecologic #oncology patients at @SitemanCenter the next day
Read 13 tweets
I will now proceed to go on a #tweetrant / #tweetorial with regards to #Pharmaceutical #biotech pricing (focus on #cancer).

Very timely, also see @WSJ wsj.com/articles/big-p… on price hikes.

For the record, no #COI / #FCOI. Feel free to contribute to this discussion.
Lets look at the problem from the @PhRMA / business perspective. And lets suppose you are a wonderful company, started by wonderful people who just want to make the world a better place (I know, not real, but stay with me for a minute).
You start with a great idea / or pipeline platform and start selling this concept to #VC #VentureCapital, and lets assume that this is actually a really good idea. What is the needed return on investment to make this worth while. A: further R&D must exceed the cost of capital.
Read 17 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!